Top Healthcare Market Research Companies in Denmark (2026 Guide)

Denmark is a strategically distinct pharmaceutical and healthcare market — with a national healthcare system operating a DKK 280 billion+ annual health budget in 2026. Despite its population of approximately 6 million, Denmark is a priority market for global pharmaceutical and biotech companies due to its unique Medicinrådet collective HTA model, AMGROS pan-regional hospital procurement system, transparent DKMA regulatory pathway, and its role as a key Nordic benchmarking market in European pharmaceutical research programmes.

Healthcare market research in Denmark is shaped by three defining structural features:

• Medicinrådet collective HTA gatekeeping: DKMA marketing authorisation does not guarantee commercial hospital access. Real-world hospital uptake depends on Medicinrådet HTA recommendation — which requires benefit documentation meeting Medicinrådet evidence standards. Medicinrådet (est. 2017, replacing RADS) makes collective recommendations for all 5 Danish Regions simultaneously, creating a single pan-Danish hospital medicine access decision unlike any other European HTA system. Positive recommendations enable Danish Regions collective implementation; negative or restricted recommendations can limit hospital access across all of Denmark.
• AMGROS centralised hospital procurement: AMGROS (Amgros I/S) conducts centralised hospital medicine procurement tenders on behalf of all 5 Danish Regions — uniquely pan-regional among Nordic hospital procurement systems. AMGROS tender success determines hospital medicine pricing and supply terms for all Danish hospital regions. Research without AMGROS tender intelligence carries significant commercial risk for hospital medicine launch teams in Denmark.
• 5-region collective implementation complexity: Denmark's 5 regions — Capital Region of Denmark, Region Zealand, Region of Southern Denmark, Central Denmark Region, and North Denmark Region — collectively implement Medicinrådet recommendations while maintaining individual regional hospital formulary committees and Sygehusapoteket pharmacy processes. Understanding regional formulary dynamics, hospital pharmacy committee behaviour, and Danish Regions procurement practices is essential for effective Danish healthcare market research.

For additional Danish context, see our Denmark pharmaceutical market research guide.

Denmark's hospital network concentrates the country's most influential specialist KOLs and innovative prescribers within a compact but strategically significant set of university and regional hospitals. Key research environments include: Rigshospitalet Copenhagen — Denmark's largest university hospital and primary oncology, haematology, transplant, and complex medicine KOL hub with national guideline leadership; Aarhus University Hospital — the Jutland region's leading academic centre with strong oncology, cardiology, and clinical trial enrolment volumes; Odense University Hospital (OUH) — the primary academic hospital for Region of Southern Denmark and a key oncology and surgery KOL centre; Herlev Hospital — a leading oncology and surgery reference centre in the Capital Region; and Aalborg University Hospital — the primary academic and tertiary centre for North Denmark Region.

KOL mapping in Denmark requires tracking influence across this geographically distributed landscape spanning Copenhagen, Aarhus, Odense, Herlev, and Aalborg — while accounting for Denmark's academic-public hospital integration and the significant influence of Copenhagen University and Aarhus University academic medical researchers on national Medicinrådet advisory structures. Danish specialist society networks — including oncology, cardiology, rheumatology, and haematology — represent a key influence channel alongside hospital appointment structures.

HCP surveys in Denmark require Danish-language protocols, verified physician recruitment, and GDPR-compliant data handling under the Danish Data Protection Act (Databeskyttelsesloven). Denmark's relatively small specialist population — particularly in rare disease, oncology, and sub-specialties — requires careful census-level or near-census recruitment strategies across all 5 Danish regions.

BioNixus conducts KOL mapping and HCP research across Denmark in oncology, cardiovascular, immunology, metabolic, rare disease, and other specialty areas — with Danish-language methodologies and Nordic regional benchmarking. See our Denmark pharmaceutical market research guide for methodology details.